The pivotal study, investigating Alex Therapeutics’ and Vicore’s standalone digital therapy (DTx) treating anxiety in patients with pulmonary fibrosis (PF), has launched in the US. The randomized clinical investigation will evaluate the impact of dCBT-PF Almee™ in adult subjects with PF for 250 patients in a 9-week program.
Alex Therapeutics, together with Pfizer, has reached the first major milestone in a clinical study of a digital therapeutic for the CBT-based treatment of tobacco dependence in Germany.
Alex Therapeutics presents positive results from the pilot phase of a clinical study for one of their digital therapies treating anxiety in patients with the rare disease IPF. The primary objective of the study was to test the functionality, user experience, and safety of the DTx, which were all found to be positive. Additionally, using GAD-7, anxiety symptoms were shown to have been reduced by an average of 4.2 points, a 49% reduction.
Clinical study investigating Alex Therapeutics’ and Vicore’s standalone digital therapy (DTx) treating anxiety in patients with pulmonary fibrosis (PF) has launched in the US. The clinical study consists of two phases; the current pilot study designed to refine the interactive nature of the therapy session, followed by a pivotal study.
Alex Therapeutics raises €3.5M in oversubscribed financing round from top tier VC investors to advance expansion in Europe and the US. This funding round will be used to accelerate Alex's growth in Europe and the US and to develop novel DTx products alongside both new and existing partners, including Pfizer.
The Stockholm-based Digital Therapeutics (DTx) company Alex Therapeutics and world-leading pharmaceutical company Pfizer have joined forces to provide evidence-based, clinically validated, and personalized digital therapies to patients. Together, the companies cover a broad range of expertise in the fields of medicine, marketing, clinical validation, AI, software development, and psychology. The partnership will initially focus on Germany, one of the world's largest unified healthcare markets.
Alex Therapeutics has received approval and funding from Vinnova to develop, optimise and clinically validate an AI-based tobacco cessation treatment tailored to India.
Alex Therapeutics and the world leading pharmaceutical company Pfizer partner to combat the tobacco epidemic and help achieve a smoking-free society. Today, the 31st of May, is the World No Tobacco Day. Alex Therapeutics and Pfizer are seeking to draw attention to the continued global tobacco problem and as well as their collaboration to combat it.
Vicore Pharma, a rare disease pharmaceutical company developing innovative medicines for fibrotic lung disorders such as idiopathic pulmonary fibrosis (IPF), today announces the signing of an agreement with Alex Therapeutics for the development of a clinically validated digital therapeutic (DTx) built on the “Alex DTx Platform”.